05:07 PM EST, 12/18/2024 (MT Newswires) -- Savara (SVRA) said late Wednesday it started a rolling submission of a biologics license application, or BLA, to the US Food and Drug Administration for Molbreevi, aimed at potentially treating autoimmune Pulmonary Alveolar Proteinosis, a rare lung disease.

The clinical-stage biopharmaceutical company said it plans to finalize the BLA submission by the end of Q1 2025 and intends to seek priority review.

Shares of Savara were up 0.3% in after-hours trading.